The FDA granted orphan drug designation to BRM424 for the treatment of neurotrophic keratitis, according to a press release from Brim Biotechnology.
The drug uses a synthetic peptide made from 29 amino acids that activate limbal stem cells to regenerate and repair the cornea. The company is also developing a candidate for dry eye disease using the same active pharmaceutical ingredient, according to the release.
Brim plans to apply for a phase 2 trial of BRM424 for neurotrophic keratitis in the United States.
“The novel regenerative effect of BRM424 could provide a new treatment option for